Adicet Bio, Inc. Announces Pricing of Public Offering of Common Stock
08 December 2021 - 5:13PM
Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company
discovering and developing allogeneic gamma delta CAR T cell
therapies for cancer and other diseases, today announced the
pricing of an underwritten public offering of 6,250,000 shares of
its common stock at a public offering price of $14.00 per share.
Adicet also granted the underwriters a 30-day option to purchase up
to an additional 937,500 shares of common stock at the public
offering price, less underwriting discounts and commissions. The
gross proceeds from the offering, before deducting underwriting
discounts and commissions and offering expenses, are expected to be
$87.5 million, excluding any exercise of the underwriters' option
to purchase additional shares. All of the shares in the offering
are to be sold by Adicet. The offering is expected to close on or
about December 10, 2021, subject to the satisfaction of customary
closing conditions.
Jefferies and Guggenheim Securities are acting as
joint book-running managers for the offering. Truist Securities is
acting as passive book-runner for the offering. BTIG, H.C.
Wainwright & Co. and JonesTrading are acting as co-managers for
the offering.
The shares are being offered by Adicet pursuant to
a shelf registration statement that was previously filed with, and
subsequently declared effective on March 30, 2021 by, the U.S.
Securities and Exchange Commission (SEC). A preliminary prospectus
supplement relating to and describing the terms of the offering was
filed with the SEC on December 7, 2021. The final prospectus
supplement relating to the offering will be filed with the SEC and
will be available on the SEC’s website at www.sec.gov. When
available, copies of the final prospectus supplement and the
accompanying prospectus relating to the offered securities may be
obtained from: Jefferies LLC, Attention: Equity Syndicate
Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY
10022, by telephone at (877) 821-7388, or by email at
prospectus_department@Jefferies.com; or Guggenheim Securities, LLC,
Attention: Equity Syndicate Department, 330 Madison Avenue, 8th
Floor, New York, NY 10017, by telephone at (212) 518-9544, or by
email at GSEquityProspectusDelivery@guggenheimpartners.com.
This press release shall not constitute an offer to
sell or the solicitation of an offer to buy these securities, nor
shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About Adicet
Adicet Bio, Inc. is a biotechnology company
discovering and developing allogeneic gamma delta T cell therapies
for cancer and other diseases. Adicet is advancing a pipeline of
“off-the-shelf” gamma delta T cells, engineered with chimeric
antigen receptors and T cell receptor-like antibodies to enhance
selective tumor targeting, facilitate innate and adaptive
anti-tumor immune response, and improve persistence for durable
activity in patients.
Forward-Looking Statements
This press release contains "forward-looking
statements" of Adicet within the meaning of the Private Securities
Litigation Reform Act of 1995, as amended, including without
limitation, statements related to the anticipated public offering
of shares. These forward-looking statements include, but are not
limited to, those relating to Adicet’s expectations regarding the
anticipated closing of the public offering. Any forward-looking
statements in this press release are based on management’s current
expectations and beliefs of future events, and are subject to a
number of risks and uncertainties that could cause actual results
to differ materially and adversely from those set forth in or
implied by such forward-looking statements. These risks and
uncertainties related to completion of the public offering on the
anticipated terms, or at all, include, but are not limited to,
market conditions and the satisfaction of customary closing
conditions related to the public offering. For a discussion of
these and other risks and uncertainties, and other important
factors, any of which could cause Adicet’s actual results to differ
from those contained in the forward-looking statements, see the
section entitled “Risk Factors” in Adicet’s most recent annual
report on Form 10-K filed on March 12, 2021 and our subsequent
quarterly reports on Form 10-Q and current reports on Form 8-K
filed with the SEC, as well as discussions of potential risks,
uncertainties, and other important factors in Adicet’s other
filings with the SEC, including those contained or
incorporated by reference in the preliminary prospectus supplement
related to the proposed public offering to be filed with the SEC.
All information in this press release is as of the date of the
release, and Adicet undertakes no duty to update this
information unless required by law.
Adicet Bio, Inc.Investor
and Media ContactsAnne Bowdidgeabowdidge@adicetbio.com
Source: Adicet Bio, Inc.
Adicet Bio (NASDAQ:ACET)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adicet Bio (NASDAQ:ACET)
Historical Stock Chart
From Apr 2023 to Apr 2024